A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)
Public ClinicalTrials.gov record NCT06178055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central Retinal Artery Occlusion (CRAO)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based therapy for CRAO. The objective of this GION study is to evaluate the efficacy and safety of KUS121 intravitreal (IVT) injection in participants with acute non-arteritic CRAO.
Study identification
- NCT ID
- NCT06178055
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 20 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2024 (Actual)
- Primary completion
- Mar 3, 2025 (Actual)
- Completion
- Nov 30, 2025 (Actual)
- Last update posted
- Feb 18, 2026
2024 – 2025
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Retina Partners | Encino | California | 91436 | — |
| Salehi Retina Institute, Inc | Huntington Beach | California | 92647 | — |
| Kaiser Permanente Oakland Med Ctr. | Oakland | California | 94611 | — |
| Florida Retina Institute | Jacksonville | Florida | 32216 | — |
| Cumberland Valley Retina Consultants | Hagerstown | Maryland | 21740 | — |
| Kresge Eye Institute/Wayne State University | Detroit | Michigan | 48201 | — |
| NYEE Infirmary of Mount Sinai | New York | New York | 10003 | — |
| UH Eye Institute | Cleveland | Ohio | 44106 | — |
| Austin Retina Associates | Austin | Texas | 78705 | — |
| Retina Consultants of Texas | San Antonio | Texas | 78240 | — |
| Retina Consultants of Texas | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06178055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06178055 live on ClinicalTrials.gov.